Nermine Moussa
Overview
Explore the profile of Nermine Moussa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
23
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aly G, Sabra S, Haroun M, Helmy M, Moussa N
Naunyn Schmiedebergs Arch Pharmacol
. 2025 Feb;
PMID: 39937256
Oral squamous cell carcinoma is a diverse complex disease. Despite the ever-expanding repertoire of anti-cancer treatments, the outcomes are often inadequate highlighting the urgent need for innovative approaches. In this...
2.
Al-Shami A, Haroun M, Essawy A, Moussa N, Abd Elkader H
Neurotoxicology
. 2024 Dec;
106():17-36.
PMID: 39617347
Bisphenol A (BPA) is an endocrine disruptor monomer that is widely used in the manufacturing of epoxy resins and polycarbonate plastics. Several lines of evidence indicate the function of the...
3.
Al-Shami A, Abd Elkader H, Moussa N, Essawy A, Haroun M
Mol Cell Biochem
. 2024 Jun;
PMID: 38941031
Bisphenol A (BPA), a common endocrine-disrupting chemical, is found in a wide range of home plastics. Early-life BPA exposure has been linked to neurodevelopmental disorders; however, the link between neuroinflammation,...
4.
Emam S, Moussa N
BDJ Open
. 2024 Apr;
10(1):29.
PMID: 38580623
Introduction: Cell signaling pathways are the biological reactions that control cell functions and fate. They also directly affect the body reactions to implanted biomaterials. It is well-known that dental implants...
5.
Alian D, Helmy M, Haroun M, Moussa N
Med Oncol
. 2024 Jan;
41(2):43.
PMID: 38170401
Drug resistance and recurrence represent a great challenge in colorectal cancer management, highlighting the urgent need for novel therapeutics. Our objective is to evaluate the influence of Abemaciclib, Celecoxib, and...
6.
Youssef M, Moussa N, Helmy M, Haroun M
Med Oncol
. 2022 Jul;
39(10):143.
PMID: 35834137
Aberrant activation of several signaling pathways has been implicated in prostate cancer (PCa) progression to castrate-resistant prostate cancer (CRPC). Phosphoinositide-3-kinase/Protein Kinase B/mechanistic Target of Rapamycin (PI3K/AKT/mTOR) and Hedgehog/GLI (Hh/GLI) pathways...
7.
El-Kishky A, Moussa N, Helmy M, Haroun M
Med Oncol
. 2022 Jul;
39(10):144.
PMID: 35834029
Despite the huge efforts employed to implement novel chemotherapeutic paradigms for lung cancer, the disease still remains a major concern worldwide. Targeting molecular pathways as Hedgehog (Hh) and Mitogen-activated protein...
8.
Agwa M, Abu-Serie M, Abdelmonsif D, Moussa N, Elsayed H, Khattab S, et al.
Int J Pharm
. 2021 Aug;
607:120965.
PMID: 34339814
Targeted delivery of cytotoxic drugs has shown great potential in cancer therapy. In this light, vitamin D3 (vit.D3)-coated micelles were fabricated to encapsulate the cytotoxic drug; etoposide (ETP). Sodium caseinate...
9.
Nasser F, Moussa N, Helmy M, Haroun M
Naunyn Schmiedebergs Arch Pharmacol
. 2020 Oct;
394(3):481-490.
PMID: 33052427
Despite the continuously growing repertoire of new and improved anti-cancer therapies, triple-negative breast cancer (TNBC) remains a clinical challenge to treat. In this sense, targeting signaling pathways such as Notch...